<DOC>
	<DOCNO>NCT03091400</DOCNO>
	<brief_summary>The purpose crossover trial investigate whether atomoxetine ( versus placebo ) improve memory function person memory deficit due multiple sclerosis .</brief_summary>
	<brief_title>Recall Enhancement Through Treatment With Atomoxetine MS ( RETAIN-MS )</brief_title>
	<detailed_description>Approximately half person multiple sclerosis ( MS ) develop memory decline , make difficult maintain gainful employment , manage household , lead fully-engaged social life . There currently validate symptomatic treatment memory deficit person MS . The study team perform fourteen week double-blind phase-two crossover randomize control trial ( RCT ) atomoxetine ( 80mg qd , six week ) versus placebo ( six week ) improve memory MS patient document memory impairment ( two-week washout phase ) . Atomoxetine non-stimulant selective norepinephrine reuptake inhibitor FDA-approved treat cognitive-behavioral symptom attention deficit / hyperactivity disorder ( ADHD ; Strattera , Eli Lilly ) . Pre-clinical evidence suggest atomoxetine may also improve memory target brain mechanism responsible memory function ( norepinephrine hippocampus ) . Twenty-four MS patient demonstrate objective memory impairment neuropsychological screening test randomly assign once-daily orally-administered atomoxetine identically-encapsulated placebo . After two-week washout period , patient switch opposite condition . The RCT perform Corinne Goldsmith Dickinson Center MS Icahn School Medicine Mount Sinai . Baseline follow-up evaluation ass change objective memory function ( Primary Outcome ) , well Secondary Outcomes patient-reported memory change , additional objective measure memory function , measure speed symbol-digit coding ( widely-used test cognition person MS ) . Tertiary / Other Outcomes examine sustain attention , process speed , work memory , fatigue , mood , manual dexterity , walk speed . The researcher predict atomoxetine lead significantly great improvement Primary Secondary memory outcome relative placebo . Consistent ADHD literature , may additional benefit atomoxetine versus placebo measure attention , process speed , work memory . Results phase 2 trial inform decision / plan possible phase 3 trial , may ultimately support use non-stimulant , once-daily atomoxetine memory treatment option MS patient .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Memory Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Diagnosis Multiple Sclerosis base Revised McDonald criterion Age 21 60 year . Patient selfreport memory decline previously high level functioning . Memory Impairment validate neuropsychological memory screening test , follow : 1. performance ≤16th percentile ( ) Rey Auditory Verbal Learning Test ( RAVLT ) Total Learning ( TL ) ( ii ) WMSIV Visual Reproduction I ( VRI ) ; b ) mean normative memory performance ( RAVLT TL WMSIV VRI ) least 1.0 standard deviation expectation base Wechsler Test Adult Reading ( WTAR ) Current stimulant medication usage . Previous diagnosis treatment ADHD neurologic condition multiple sclerosis ( e.g. , traumatic brain injury , epilepsy ) Clinical relapse MS within 60 day screening , Change diseasemodifying therapy within 90 day screen , Below average estimate premorbid intelligence ( WTAR , &lt; 16th percentile ) , Severe cognitive impairment indicate MiniMental Status Examination ( MMSE ) &lt; 24/30 . Contraindications atomoxetine use : ( ) selfreported history suicidal ideation within last twelve month ( Columbia Suicide Severity Rating Scale ) , ( b ) diagnosis bipolar illness , ( c ) moderate severe current depressive symptomatology ( Beck Depression Inventory Fast Screen ≥ 9 ) , ( ) diagnosis hepatic disease , ( e ) narrow angle glaucoma , ( f ) pheochromocytoma , ( g ) monoamine oxidase inhibitor within 14 day study drug start , ( h ) take strong CYP2D6 inhibitor ( e.g. , paroxetine , fluoxetine , quinidine ) , ( ) diagnosis heart disease , ( j ) pregnant planning pregnancy study period , ( k ) breastfeeding , ( l ) hypersensitivity atomoxetine component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Memory Disorders</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Atomoxetine Hydrochloride</keyword>
</DOC>